Lotus Pharmaceutical Co., Ltd.

TWSE:1795 Stock Report

Market Cap: NT$68.5b

Lotus Pharmaceutical Future Growth

Future criteria checks 5/6

Lotus Pharmaceutical is forecast to grow earnings and revenue by 21.6% and 12.4% per annum respectively. EPS is expected to grow by 21.1% per annum. Return on equity is forecast to be 22.8% in 3 years.

Key information

21.6%

Earnings growth rate

21.1%

EPS growth rate

Pharmaceuticals earnings growth8.2%
Revenue growth rate12.4%
Future return on equity22.8%
Analyst coverage

Low

Last updated21 Jan 2025

Recent future growth updates

Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 16
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Recent updates

Market Cool On Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Earnings

Dec 04
Market Cool On Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Earnings

Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 16
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Nov 14
Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Oct 23
Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Jul 18
Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Earnings and Revenue Growth Forecasts

TWSE:1795 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202622,2436,565N/A9,3301
12/31/202521,2716,1296,3156,7475
12/31/202418,4694,8104,7726,1915
9/30/202417,5944,3333,2934,622N/A
6/30/202416,9334,0142,4554,071N/A
3/31/202416,6323,9481,7173,325N/A
12/31/202316,9584,106-1,6611,614N/A
9/30/202316,7103,873-9183,440N/A
6/30/202317,5274,707-1,2112,974N/A
3/31/202315,9953,769-8943,251N/A
12/31/202214,6333,0216503,719N/A
9/30/202214,2643,1051812,198N/A
6/30/202211,9321,374-2272,012N/A
3/31/202212,4861,401-1,892496N/A
12/31/202112,6491,403-1,496120N/A
9/30/202112,9771,470-1,029421N/A
6/30/202112,8061,400-1,18226N/A
3/31/202112,0191,3443711,447N/A
12/31/202010,7291,027-491,949N/A
9/30/202010,802848-5521,619N/A
6/30/20209,933769-8631,116N/A
3/31/20209,307519-980905N/A
12/31/20199,611663-686420N/A
9/30/20198,130596-523266N/A
6/30/20197,6934631691N/A
3/31/20197,27835939720N/A
12/31/20186,42999403797N/A
9/30/20186,53738401774N/A
6/30/20186,53519N/A657N/A
3/31/20186,477110N/A623N/A
12/31/20176,42422N/A591N/A
9/30/20176,072-171N/A696N/A
6/30/20175,897-252N/A965N/A
3/31/20175,913-270N/A1,186N/A
12/31/20165,903-134N/A1,233N/A
9/30/20165,89678N/A1,490N/A
6/30/20165,910126N/A1,378N/A
3/31/20165,653198N/A1,223N/A
12/31/20155,522104N/A1,078N/A
9/30/20154,712-102N/A436N/A
6/30/20153,879-204N/A-531N/A
3/31/20153,125-312N/A-886N/A
12/31/20142,310-442N/A-1,032N/A
9/30/20142,201-307N/A-1,310N/A
6/30/20142,152-269N/A-503N/A
3/31/20142,411-330N/A-379N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1795's forecast earnings growth (21.6% per year) is above the savings rate (1.1%).

Earnings vs Market: 1795's earnings (21.6% per year) are forecast to grow faster than the TW market (17.5% per year).

High Growth Earnings: 1795's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1795's revenue (12.4% per year) is forecast to grow faster than the TW market (11.3% per year).

High Growth Revenue: 1795's revenue (12.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1795's Return on Equity is forecast to be high in 3 years time (22.8%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 13:18
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lotus Pharmaceutical Co., Ltd. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCapital Securities Corporation
Jianzheng WuCapital Securities Corporation
Hsuan ChenKGI Securities Co. Ltd.